A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples